Teprotumumab, a monoclonal antibody that inhibits IGF-1R, is the first disease-modifying therapy approved in the United States for the treatment of TAO in the United States (Nie and Lamb, 2022). This evidence concerns the gene IGF1R and thromboangiitis obliterans.